Saturday, November 15, 2014 | 11:00 AM - 4:00 PM
Moderator: Jan-Philipp Kruse (Catenion)
This course gives professionals from inside and outside the pharmaceutical industry—including students and postdocs—a much better understanding of how the R&D and business development and licensing processes operate.
Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM
Speakers: Matthew D. Breyer (Eli Lilly, Indianapolis, IN), Frank C. Brosius (University of Michigan Medical School, Ann Arbor, MI), Benjamin D. Humphreys (Harvard Institutes of Medicine, Boston, MA), Matthias Meier (F. Hoffmann-LaRoche Ltd, Basel, Switzerland), Shahnaz Shahinfar (S. Shahinfar Consulting, Inc. and The Children's Hospital of Philadelphia), Katalin Susztak (University of Pennsylvania, Philadelphia, PA), Aliza Thompson (US Food & Drug Administration, Silver Spring)
Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.
Tuesday, January 27, 2015 | 8:30 AM - 4:30 PM
Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School)
Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle MA), Dario Neri (Philogen, Zurich, Switzerland), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology)
Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.
Tuesday, February 24, 2015 | 8:30 AM - 4:30 PM
Speakers: James Inglese (National Center for Advancing Translational Sciences), Yi Yang (Novartis Institutes for Biomedical Research)
The emergence of genome editing technologies such as TALEN and CRISPR/Cas9 are revolutionizing our ability to rapidly engineer mammalian systems. This symposium explores the frontiers of genome editing and potential to aid therapeutic development.
Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM
Speaker: Michael S. Conte (University of California-San Francisco), Milan Fiala (David Geffen School of Medicine at UCLA), Gabrielle Fredman (Columbia University), Bruce Levy (Harvard University, Brigham and Women's Hospital), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Harvard Medical School), Mauro Perretti (Queen Mary University of London), Charles N. Serhan (Brigham & Women's Hospital, Harvard Medical School), Patricia J. Sime (University of Rochester School of Medicine), Rudolph E. Tanzi (Massachusetts General Hospital)
Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.
Friday, October 10, 2014 | 8:00 AM - 3:15 PM
Keynote Speaker: The Honorable Patrick J. Kennedy
Former United States Representative, Rhode Island; One Mind for Research; Kennedy Forum
This conference will explore the translation of recent breakthroughs in neuroscience into therapies for the more than twenty-five percent of Americans suffering from mental illnesses such as schizophrenia, depression, fear and anxiety disorders, autism, and other psychiatric disorders. A keynote lecture by The Honorable Patrick J Kennedy will address strategies to simultaneously abolish the stigma surrounding mental illness in order to fully realize the potential of these new treatments to improve mental health.
Thursday, October 9, 2014 | 8:00 AM - 4:00 PM
Keynote Speakers: Neesha Dhani (Princess Margaret Hospital, Toronto), Steven D. Leach (Memorial Sloan Kettering Cancer Center)
Speakers: Gregory Beatty (University of Pennsylvania Perelman School of Medicine), Neesha C. Dhani (Division of Medical Oncology & Hematology, University Health Network, Princess Margaret Cancer Centre/Ontario Cancer Institute), Mikala Egeblad (Cold Spring Harbor Laboratory), Douglas T. Fearon (Weill Cornell Medical College and Cold Spring Harbor Laboratory), Elda Grabocka (Department of Biochemistry and Molecular Pharmacology, NYU Langone School of Medicine), Costas A. Lyssiotis (Weill Cornell Medical College ), George Miller (NYU Langone Medical Center), Michael Ports (Gilead Sciences), Curtis B. Thompson (Halozyme Therapeutics, Inc)
Pancreatic cancer patients currently have limited therapeutic options. This symposium explores breakthroughs in the pathogenesis and progression of pancreatic cancer, and efforts to exploit key vulnerabilities for novel therapeutic interventions.
Tuesday, September 30, 2014 | 8:30 AM - 5:00 PM
Keynote Speaker: Nobel Laureate Robert J. Lefkowitz (Duke University Medical Center)
Speakers: John A. Allen (Pfizer), Laura Bohn (The Scripps Research Institute - Florida), Marc G. Caron (Duke University Medical Center), Jonathan A. Javitch (Columbia University and New York State Psychiatric Institute), Terry Kenakin (University of North Carolina School of Medicine), Bryan L. Roth (University of North Carolina School of Medicine), JoAnn Trejo (University of California, San Diego), Jonathan D. Violin (Trevena Inc.)
Hear academic, industry, basic and translational researchers, including Nobel Laureate Robert Lefkowitz (Duke University Medical Center) and discuss the development of functionally selective GPCR-biased ligands for CV and CNS disease drug discovery.
Edited by George R. Uhl
(National Institutes of Health, Baltimore, Maryland)
The sixth installment of this annual series explores molecular and translational/therapeutic aspects of addiction.
Keynote Speaker: Robin Franklin (Wellcome Trust – MRC Cambridge Stem Cell Institute, University of Cambridge)
This eBriefing highlights biological and clinical findings in remyelination. It also features new techniques for imaging myelin and screening molecular targets, as well as therapeutics that promote remyelination.
Edited by Annals of the New York Academy of Sciences
This Annals volume presents three meeting reports: (1) Production and supply of high-quality food protein for human consumption: sustainability, challenges, and innovations; (2) Clinical and economic outcomes of nutrition interventions across the continuum of care; and (3) Antibody–drug conjugates: an emerging modality for the treatment of cancer.
Organizers: Howard Fillit (Alzheimer's Drug Discovery Foundation), Kevin J. Lee (Lawrence Ellison Foundation), and Jennifer Henry (The New York Academy of Sciences)
This eBriefing explores advances in the science of aging and in drug discovery for Alzheimer's and other neurodegenerative diseases.
Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.
Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.
December 18, 2009
We sit down with science photographer Felice Frankel and nanotechnology pioneer and Harvard chemist George Whitesides to hear about their new book on nanoscience, No Small Matter.
Visit the lab of Hunter College's Jill Bargonetti, a biologist researching cancer. Her team studies P53, a natural tumor-suppressor protein found in our bodies with a Dr. Jekyll and Mr. Hyde personality.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
April 28, 2009
Protein kinases play a key role in almost every major pathway in eukaryotic cells. Structural approaches, including a new method called fragment-based drug design, are identifying potential targets against diseases including cancer.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.